Frequently Asked Questions

---

RP Gene Research Foundation is a charitable organization dedicated to providing funding to medical research institutions focused on finding a cure for Retinitis Pigmentosa. 

You can donate to RP Gene Research Foundation through our website by clicking on the 'Donate' button on the homepage.

Yes, all donations made to RP Gene Research Foundation are tax-deductible.

Retinitis pigmentosa (RP) typically starts in childhood or early adulthood, although the age of onset can vary. 

• Childhood onset: Some children may experience symptoms as early as 5-10 years old. 
• Early adulthood onset: Most people with RP develop symptoms between the ages of 10 and 30. 
• Late onset: In rare cases, RP may not manifest until later in adulthood. 

While symptoms can start at different ages for each individual, the first noticeable symptom, often night blindness, commonly appears in the teen years and gradually worsens. Other early signs may include difficulty seeing in dim light and reduced peripheral vision. The age of onset can depend on the specific genetic mutation causing RP. It's important to note that RP is a progressive disease, meaning the symptoms will worsen over time.  

Retinitis pigmentosa (RP) is diagnosed through a combination of tests performed by an eye doctor, often an ophthalmologist or retina specialist.  Here's how they diagnose RP:

1. Comprehensive Eye Exam:

• Dilated Eye Exam: The eye doctor will dilate your pupils with eye drops to get a clear view of the retina, located at the back of the eye.
• Ophthalmoscopy: Using an ophthalmoscope, the doctor will look for characteristic signs of RP on the retina, such as bone spicule-shaped pigment deposits. 

2. Visual Field Testing:

• Perimetry Tests: These tests measure your peripheral (side) vision to detect blind spots or a narrowed field of vision, common in RP. 

3. Electrophysiological Tests:

• Electroretinogram (ERG): This test measures the electrical activity of the retina's light-sensitive cells (photoreceptors) in response to flashes of light. It helps determine how well the retina is functioning and can detect even early photoreceptor damage. 

4. Imaging Tests:

• Retinal Photography: A camera takes detailed pictures of your retina to document and track the progression of the disease.
• Optical Coherence Tomography (OCT): This non-invasive test uses light waves to create cross-sectional images of the retina, allowing the doctor to analyze its structure and thickness.
• Fundus Autofluorescence (FAF): This test uses blue light to image the retina's natural autofluorescence, highlighting areas of retinal pigment epithelial (RPE) cell dysfunction and degeneration. 

5. Genetic Testing:

• Blood or Saliva Sample: Genetic testing involves analyzing a blood or saliva sample to identify specific gene mutations associated with RP.
• Genetic Counseling: A genetic counselor can explain the testing process, interpret the results, and discuss the implications for the patient and their family. 

Why are these tests important?

• Confirming the Diagnosis: These tests help confirm the presence of RP and rule out other eye conditions.
• Identifying the Specific Type of RP: Genetic testing can help pinpoint the exact gene mutation causing the disease, which can provide insights into how the disease may progress.
• Monitoring Disease Progression: Retinal imaging and visual field tests help track how the disease is affecting the patient's vision over time.
• Assessing Potential for Treatment: Knowing the genetic cause can help determine if the patient might be eligible for future gene therapies or clinical trials. 

In summary, diagnosing Retinitis Pigmentosa involves a comprehensive evaluation of the patient's symptoms, a thorough eye exam, and specialized tests like electroretinography and genetic testing to confirm the diagnosis and determine the specific type of RP. 

 Retinitis pigmentosa (RP) is primarily a genetic disorder caused by mutations in genes involved in photoreceptor function. These mutations can be inherited in different patterns: 

1. Autosomal Recessive Inheritance:

• This is the most common pattern, accounting for about 60% of cases.
• It requires inheriting a mutated gene from both parents.
• Parents are typically carriers and do not have the condition themselves.
• Children have a 25% chance of inheriting RP, a 50% chance of being a carrier, and a 25% chance of inheriting neither the gene nor the disorder.
• This form of RP often starts earlier in life with night blindness in childhood. 

2. Autosomal Dominant Inheritance:

• This pattern accounts for about 30% to 40% of cases.
• Only one copy of the mutated gene from one parent is sufficient to cause the condition.
• The affected parent typically has the disorder.
• Each child has a 50% chance of inheriting the mutated gene and thus the disorder.
• This form tends to be less severe and progress more slowly, with symptoms often starting in adulthood. 

3. X-linked Recessive Inheritance:

• This pattern is responsible for about 5% to 15% of cases.
• The mutated gene is located on the X chromosome.
• Males (with one X chromosome) are primarily affected.
• Females (with two X chromosomes) can be carriers, but are less likely to experience severe vision loss.
• Carrier mothers have a 50% chance of having affected sons and a 50% chance of having carrier daughters.
• Affected fathers will pass the mutation to all their daughters (who become carriers) but not to their sons.
• This form often leads to the most severe vision loss. 

4. Sporadic Cases:

• Approximately 50% of RP cases have no documented family history.
• This can occur due to new gene mutations (de-novo mutations) that arise spontaneously in the individual, or in some cases, the inheritance pattern may be unidentifiable. 

Important Notes:

• Genetic Counseling: If RP is suspected in a family, genetic counseling is highly recommended. A genetic counselor can help determine the inheritance pattern, discuss the risk of passing the condition to children, and provide information about genetic testing.
• Genetic Testing: Genetic testing can help identify the specific gene mutation causing RP and provide a more accurate prognosis. 

Understanding the inheritance pattern of RP is crucial for diagnosis, prognosis, and genetic counseling.  

Retinitis pigmentosa (RP) is a highly genetically diverse group of disorders, meaning that mutations in many different genes can lead to the condition. Researchers have identified over 80 genes associated with both syndromic (affecting other organs besides the eye) and non-syndromic forms of RP.  Some of the most common and well-studied genes include: 

• RHO (Rhodopsin): This gene is involved in autosomal dominant RP and accounts for a significant percentage of cases, ranging from 20-30%. It is also responsible for approximately 10% of all RP cases in Europe and the United States. RHO mutations can also lead to autosomal recessive RP and autosomal dominant congenital stationary night blindness (CSNB).
• USH2A: Mutations in this gene are a leading cause of autosomal recessive RP and also the most common cause of Usher syndrome type II (a syndromic form of RP). It accounts for 10-15% of all autosomal recessive RP cases.
• RPGR: This gene is linked to X-linked recessive RP, which is known for its more severe form of vision loss. RPGR mutations account for approximately 70-80% of all X-linked cases.
• PRPH2 (RDS): This gene is associated with autosomal dominant RP. Mutations in PRPH2 can lead to a range of phenotypes, including macular degeneration and other complex maculopathies.
• RP1: Mutations in this gene can cause both autosomal dominant and recessive forms of RP. The inheritance pattern can depend on the type and position of the mutation.
• PRPF31: This gene is a significant cause of autosomal dominant RP and is known for incomplete penetrance, meaning not all individuals with a mutation develop symptoms. It accounts for 1-8% of adRP cases.
• ABCA4: This gene is associated with autosomal recessive RP and is one of the most commonly mutated genes in this category. It is also associated with recessive macular dystrophy and recessive cone-rod dystrophy.
• CRB1: This gene is associated with autosomal recessive RP and is also linked to recessive Leber congenital amaurosis (LCA).
• EYS: This gene is a common cause of autosomal recessive RP, especially in certain populations. It is the largest eye gene and plays a role in the structural integrity of the outer segment of photoreceptors.
• PDE6A and PDE6B: These genes are involved in the phototransduction cascade and can cause autosomal recessive RP.
• RPE65: This gene is linked to autosomal recessive RP and is known for its association with Leber congenital amaurosis (LCA)/early-onset severe retinal dystrophy (EOSRD). Gene therapy is available for patients with mutations in this gene.
• CRX: This gene is a transcription factor involved in photoreceptor development and can cause both autosomal dominant and recessive forms of RP.
• RP2: This gene is another important cause of X-linked recessive RP, accounting for about 10% of cases. Patients with RP2 mutations tend to experience a faster decline in central vision due to early macular atrophy.
• Digenic Inheritance: In rare cases, RP can result from mutations in two different genes, such as PRPH2 and ROM1. This is known as digenic RP.

Important Notes:

• Genetic Testing: Genetic testing plays a crucial role in diagnosing RP and identifying the specific gene mutation responsible for the condition in an individual.
• Genetic Counseling: If RP is suspected, it is recommended to seek genetic counseling to understand the specific gene involved, its inheritance pattern, and the implications for the individual and their family members. 

The identification of these and many other genes associated with RP is a key step towards developing effective therapies, including gene therapy, to treat this complex group of diseases.  

The formation of cataracts in individuals with Retinitis Pigmentosa (RP) is complex and not fully understood, but current research suggests several contributing factors. The most likely explanation points to the following mechanisms: 

1. Inflammation:

• RP involves a chronic inflammatory response within the eye, driven by the degeneration of photoreceptor cells and retinal pigment epithelial (RPE) cells.
• This inflammation leads to increased levels of inflammatory cytokines and chemokines in the eye's fluids, such as interleukin (IL)-2, IL-6, IL-10, interferon γ, and monocyte chemoattractant protein-1 (MCP-1).
• These inflammatory mediators can diffuse into the lens, affecting the lens epithelial cells' normal functions and contributing to cataract formation.
• The inflammation-induced changes in the intraocular environment are believed to play a critical role in cataract development in RP patients, similar to how inflammation contributes to cataracts in conditions like uveitis.

2. Oxidative Stress:

• The degeneration of photoreceptors, particularly the rod outer segments, generates reactive oxygen species (ROS) and lipid peroxidation products.
• These toxic substances can spread into the lens, leading to oxidative stress and damage to lens proteins, particularly crystallins.
• Oxidative stress disrupts the normal structure and transparency of the lens, causing it to become cloudy and opacify.

3. Lens Epithelial Cell Dysfunction:

• The lens epithelium, a layer of cells on the front surface of the lens, acts as a barrier that regulates the movement of fluids and nutrients into and out of the lens.
• In RP patients, abnormalities in the lens epithelium, such as holes and thinning, may allow excessive fluid to enter the lens, disrupting its internal structure and promoting cataract formation.
• This disruption of lens epithelial cell function can also lead to changes in the lens's metabolic balance and water content, further contributing to cataract development.

4. Accumulation of Degenerative Products:

• The breakdown products from degenerating photoreceptors and RPE cells may accumulate in the lens, further contributing to lens opacity. 

It's important to note that the exact interplay and relative contributions of these factors are still being investigated, but inflammation and oxidative stress are widely considered the primary drivers of cataract formation in the context of RP. 

Currently, there is no cure for Retinitis Pigmentosa (RP). However, significant research is underway, particularly in the area of gene therapy and cell therapy, that offers hope for future treatments that may slow vision loss or even restore some vision. Here's a summary of the current situation and promising avenues of research:

Current Treatments:

• Gene Therapy:
  • Luxturna® (voretigene neparvovec-rzyl): This is the first FDA-approved gene therapy for inherited retinal diseases and targets mutations in the RPE65 gene. This gene is essential for proper vision, and mutations in both copies of the RPE65 gene can lead to conditions like Leber congenital amaurosis (a severe form of RP). Luxturna provides a functional copy of the RPE65 gene, improving vision in eligible patients.
  • Ongoing Research: Numerous gene therapy trials are exploring treatments for other genes involved in RP, including RPGR, USH2A, and RHO. These therapies aim to replace faulty genes or introduce genetic material that supports retinal cell survival.

• Low Vision Aids and Rehabilitation: These are important for helping individuals adapt to vision loss and maintain independence. This includes using special magnifying glasses, computer programs that translate visual information into spoken words, and occupational therapy programs.

• Vitamins and Supplements: Certain supplements, such as lutein and fish oil (containing DHA), may help slow down RP progression in some cases. However, studies have shown mixed results regarding the overall effectiveness of vitamin A and DHA supplementation for RP.

• Optogenetics: This approach utilizes gene therapy to make retinal cells that are not normally light-sensitive responsive to light. This technology has shown promise in clinical trials, with some patients showing improved visual acuity.

• Retinal Prostheses: Devices like the Argus II are surgically implanted to provide some basic vision restoration in patients with severe vision loss, enabling them to see lines and edges. While new Argus II implants are no longer available, other similar devices are in development.

Promising Future Treatments:

• Cell Therapy:
  • Stem Cell Therapy: Research into using stem cells to replace damaged retinal cells or provide supportive factors to promote retinal cell survival is a major area of focus.
  • CD34+ Stem Cells: A study at UC Davis found that administering CD34+ stem cells into the eyes of RP patients was safe and may offer therapeutic benefits.

• Other Gene Therapies:
  • Mutation-Agnostic Therapies: Some gene therapies are being developed to work regardless of the specific gene mutation causing RP, offering hope for a wider range of patients.
  • CRISPR-Based Gene Editing: This technology holds the potential to edit or correct the mutated genes responsible for RP.

• Photoswitch Therapies: These involve using molecules that bestow light sensitivity to surviving retinal cells. Kiora Pharmaceuticals reported some vision restoration in a clinical trial using this approach. 

In conclusion, while there's no cure for RP yet, the landscape of treatment is rapidly evolving. Gene therapy, particularly the approved Luxturna treatment for RPE65 mutations, represents a significant step forward. Ongoing research into other gene therapies, stem cell-based treatments, and optogenetics offers exciting prospects for slowing or even reversing vision loss caused by RP in the future.  

At present, there is no known way to fully reverse the damage caused by Retinitis Pigmentosa (RP) and completely restore vision. RP is a progressive, inherited eye disease where photoreceptor cells in the retina (rods and cones) break down over time, leading to vision loss. The damage to these cells cannot be completely undone with current treatments. However, the field of RP research is highly active, with promising advancements in therapies and treatments that aim to slow or even partially reverse the vision loss associated with the disease. 

 Important notes:

• Most of these therapies are still in clinical trials.
• The effectiveness of these treatments may vary depending on the individual's specific gene mutation and the stage of the disease.
• Low vision aids and rehabilitation programs are crucial for helping individuals adapt to vision loss and make the most of their remaining vision. 

In summary, while there is no cure for RP, research and clinical trials are exploring various approaches, including gene therapy, cell therapy, and optogenetics, that offer the potential to slow or partially reverse the vision loss associated with this condition. 

Franciscus Cornelius Donders, a Dutch ophthalmologist, is credited with discovering and naming retinitis pigmentosa (RP) in 1857. While his colleague, A.C. van Trigt, provided the first description of RP through an ophthalmoscope in 1853, Donders formally identified and named the condition. 

Here's a more detailed explanation:

• Early Observations: Prior to Donders, ophthalmologists lacked the tools to examine the living retina's interior. The invention of the ophthalmoscope in 1851 allowed for the visualization of the fundus, enabling the correlation of symptoms with observable changes. 

• Van Trigt's Contribution: A.C. van Trigt, a student of Donders, used the ophthalmoscope to examine a patient with night blindness and visual field constriction, noting pigment deposits and retinal changes. He published his findings in 1853. 

• Donders' Recognition: In 1857, Donders officially recognized and named the condition "retinitis pigmentosa," acknowledging the pigment deposits and retinal degeneration characteristic of the disease. 

• Significance: RP is now understood as a group of inherited retinal dystrophies causing progressive photoreceptor degeneration.